Calcifediol extended release - OPKO Renal

Drug Profile

Calcifediol extended release - OPKO Renal

Alternative Names: CTAP-101; CTAP101 Capsules; Modified-release calcifediol - OPKO; Rayaldee; Rayaldy

Latest Information Update: 25 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cytochroma
  • Developer OPKO Renal
  • Class Calcium regulators; Osteoporosis therapies; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Secondary hyperparathyroidism
  • Phase I Bone disorders

Most Recent Events

  • 01 Mar 2017 OPKO Renal and Vifor Fresenius Medical Care Renal Pharma plan a phase II trial for Secondary hyperparathyroidism in 2H 2017
  • 15 Dec 2016 Biomarkers information updated
  • 23 Nov 2016 Launched for Secondary hyperparathyroidism in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top